anti-keratin 17 (ab53707, Abcam, Cambridge, UK), anti-NRF2 (#12721, Cell Signaling Technologies, MA, USA), anti-phospho-NRF2 (AF1609, Beyotime, Shanghai, China), anti-IL-1 (#12703, Cell Signaling Technologies, MA, USA), anti-NQO1 (AF7614, Beyotime, Shanghai, China), anti-phospho-STAT3 (Tyr705) (#9145, Cell Signaling Technology, MA, USA), anti-STAT3 (#12640, Cell Signaling Technology, MA, USA), anti-phospho-NF-B p65 (#3033, Cell Signaling Technology, MA, USA), anti-NF-B p65 (#8242, Cell Signaling Technology, MA, USA), anti-phospho-IB (#2859, Cell Signaling Technology, MA, USA), anti-IB (#4812, Cell Signaling Technology, MA, USA) and GAPDH (BS60630, Bioworld Technology Inc., MN, USA)
Disclaimer: All professional treatments are strictly recommended to be performed by certified physicians
Since HEDS contains no glutathione moiety, alterations at the scaffold site could provide further insights regarding GSSEtOH as a potential reaction intermediate
Be careful when using around the eye area
These in-organ changes in energy metabolism are also reflected in the plasma metabolome after ischemic AKI, which is characterized by the depletion of numerous amino acids and energy substrates 6
Protocol as for acetaminophen toxicity: 140 mg/kg IV initially: slow bolus not constant rate infusion (ammonia toxicity) then 70 mg/kg IV or PO x 3-6 (or more) treatments given at 8 to 12 hour intervals